Serum C-Terminal Agrin Fragment With Acute and Long-Term Exercise and Angiotensin II Type I Receptor Blockade

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

The aim of this study was to investigate the influence of a single bout (1EX) or 48 bouts (48EX) of heavy resistance exercise (EX), with or without angiotensin II type I receptor blocker (losartan (LOS)) supplementation, on serum CAF levels in healthy older men.

Why It Was Studied

Sarcopenia represents a major clinical and societal challenge facing rapidly aging populations.

C-terminal agrin fragment (CAF) is the most commonly used blood-based biomarker of neuromuscular junction degradation in aging, inactivity and disease, but large unexplained interindividual variation exists, limiting its diagnostic and prognostic value.

Who Took Part

According to the abstract, 25 participants were involved.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

Eighty-three healthy, normotensive older men were enrolled in one of two randomized placebo (PLA) controlled trials. 1EX: 25 participants (EX ± LOS), with a mean age of 70 ± 7 years, had blood drawn before and after (4.5 h, Days 1, 4 and 7) a single bout of unilateral heavy resistance exercise of the quadriceps muscles. 48EX: at baseline, and after 8 and 16 weeks of a progressive heavy resistance exercise program, 58 participants (LOS-EX, n = 20; LOS-SED, n = 20; PLA-EX, n = 18), with a mean age of 72 ± 5 years, had blood drawn, and specific force (strength per unit mass) was measured by dynamometer and magnetic resonance imaging of the quadriceps muscles.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

Serum CAF was measured by ELISA.

What Was Measured

PubMed files the paper under topics including Agrin, Exercise, Biomarkers, Angiotensin II Type 1 Receptor Blockers, Peptide Fragments, Resistance Training and Receptor, Angiotensin, Type 1.

The authors tagged it with the keywords aging, angiotensin II type I receptor, hypertrophy, neuromuscular system, neuroprotection and strength training.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Angiotensin II in 25 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Angiotensin II compound page, all human trials.